# South America Organ On Chip Market > South America Organ-On-Chip Market Research Report By Organ Type (Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, Human-on-Chip), By Application (Drug Discovery, Toxicology Research, Others), By End-User (Pharmaceutical Companies, Research Organizations, Others) andBy Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 3.72% - **2024:** $ 32.85 Million - **2025:** $ 34.08 Million - **2035:** $ 49.1 Million - **Key Players:** Emulate (US), TissUse (DE), Mimetas (NL), Organovo (US), Synlogic (US), Hesperos (US), InSphero (CH), Reinnervate (GB), Tissot (FR) **Report ID:** MRFR/MED/49556-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-organ-on-chip-market-51313 --- ## Market Summary ## **South America Organ-On-Chip Market Overview** As per MRFR analysis, the South America Organ-On-Chip Market Size was estimated at 6.74 (USD Million) in 2023.The South America Organ-On-Chip Market Industry is expected to grow from 7.52(USD Million) in 2024 to 32.05 (USD Million) by 2035. The South America Organ-On-Chip Market CAGR (growth rate) is expected to be around 14.083% during the forecast period (2025 - 2035). ### **Key South America Organ-On-Chip Market Trends Highlighted** The South America [Organ-On-Chip market](../../../reports/organ-on-chip-market-8498) is experiencing significant growth because of investment in biotechnology and pharmaceuticals. Government initiatives in Brazil and Argentina have been fostering new health technology innovation, which is good for organ-on-chip R&D. This growing interest is also fueled by the increasing need for alternative testing procedures that ethically go without sharpening the lion's share of animal testing, which is increasingly becoming favorable around the world. South America in particular has great untapped potential considering the collaboration between academic institutions and industries. Local universities are beginning to work with biotech companies to design more advanced organ-on-chip models for drug screening and disease modeling. Strengthening research in South America fosters growth because they design region-specific solutions to appeal to investors and bolster technological growth. Recently, there has been an increase in attention given to personalized medicine where organ-on-chip technology is critical. Researchers from South America are putting more effort into developing region specific disease mimicking chips that would enable localized treatment and improve patient care. Moreover, the surge of precision medicine programs in countries like Chile is fostering further investment in organ-on-chip technologies for the creation of tailored treatments. This area is also experiencing increased focus on policy regulations aimed at boosting the adoption of these technologies, which is vital for the development of clinical practice and better healthcare services in South America. ## **South America Organ-On-Chip Market Drivers** ### **Rising Demand for Personalized Medicine** The South America Organ-On-Chip Market Industry is driven by the increasing demand for personalized medicine, which has risen due to the growing prevalence of chronic diseases. According to a report from the Pan American Health Organization, chronic diseases accounted for approximately 75% of all deaths in the region in 2019. This high percentage highlights the need for innovative medical solutions like organ-on-chip technologies, which can model human organs and optimize drug testing and treatment plans.Organizations such as the Brazil's National Health Surveillance Agency (ANVISA) are pushing for regulatory frameworks that encourage the development and use of personalized medicine solutions, further propelling the growth of the market in South America. ### **Government Investment in Biotechnology** Government initiatives in South America focused on biotechnology and innovation are a significant driver for the South America Organ-On-Chip Market Industry. For instance, Brazil's Federal Government launched the National Bioeconomy Strategy in 2020, which allocated substantial funding towards Research and Development in biotechnological ventures. This strategy is essential for fostering advancements in organ-on-chip technologies which provide a more ethical and efficient alternative to animal testing.As more countries embrace biotechnological advancements, the market is expected to receive a considerable boost from this governmental support. ### **High Prevalence of Cardiovascular Diseases** The South America Organ-On-Chip Market Industry is also fueled by the high prevalence of cardiovascular diseases (CVD) in the region. According to the World Health Organization, it was estimated that over 1 million people in South America die each year from CVD, which represents approx 31% of all global deaths from such conditions. This alarming statistic has prompted healthcare organizations and researchers to invest heavily in technologies that can help in understanding and treating heart diseases effectively.Organizations such as the Argentine Society of Cardiology are advocating for innovative research, thus creating a burgeoning need for organ-on-chip platforms to simulate cardiovascular conditions for better treatment outcomes. ## **South America Organ-On-Chip Market Segment Insights:** ### **Organ-On-Chip Market Organ Type Insights** The South America Organ-On-Chip Market has been gaining significant traction within the biotechnology and pharmaceutical sectors, primarily driven by its innovative approach to drug development and disease modeling. This market is segmented by Organ Type, encompassing vital components such as Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, and Human-on-Chip. Each segment plays a crucial role; for instance, the Lung-on-Chip mimics human lung physiology, serving as a critical tool for respiratory disease research and vaccine development.  This is particularly essential given the increasing prevalence of respiratory diseases in South America, where air quality issues are prominent.The Heart-on-Chip is of particular interest due to its applications in cardiovascular disease research, which remains a leading cause of morbidity and mortality in the region. By providing a more accurate model for heart conditions, researchers can develop better-targeted therapies and assess drug safety with greater precision. The Liver-on-Chip, on the other hand, addresses the need for effective hepatotoxicity screening for drugs.  Given the rise in liver-related ailments in South America, this segment is becoming increasingly meaningful in the context of drug development and personalized medicine.The Intestine-on-Chip reflects a growing focus on gastrointestinal disorders, which affect a considerable proportion of the population in South America, highlighting the importance of digestive health. It enables researchers to create more accurate models for studying inflammatory bowel disease and other gastrointestinal disorders, thereby promoting advancements in treatment methodologies. In the same vein, the Kidney-on-Chip caters to renal disease research, aiming to tackle the rising incidents of chronic kidney disease within the region.  Finally, the Human-on-Chip integrates multiple organ systems, facilitating a more holistic approach to understanding human physiology and drug interactions in a microenvironment that simulates real-life conditions. This segment emphasizes the multi-organ connectivity that is vital for studying systemic diseases and comprehensive drug responses.  The increasing reliance on these innovative platforms is primarily fueled by their potential to reduce the dependency on animal testing, thereby aligning with ethical standards and regulatory developments focused on humane and sustainable research practices. As such, the segmentation of the South America Organ-On-Chip Market by organ type underscores its role in transforming research methodologies and therapeutic development across various health domains. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Organ-On-Chip Market Application Insights** The Application segment of the South America Organ-On-Chip Market plays a crucial role in advancing biomedical and pharmaceutical research. With the growing need for efficient and ethical drug development processes, drug discovery has emerged as a leading application, enabling researchers to improve success rates and minimize failures in clinical trials. Toxicology research significantly benefits from Organ-On-Chip technology by providing more accurate predictions of human responses to toxic substances, which enhances safety assessments and regulatory compliance.Additionally, other applications within this segment address diverse areas such as personalized medicine and disease modeling.  This diversification in applications drives the overall market growth by responding to the increasing demands for innovative solutions in healthcare. Moreover, the expansion of research initiatives in South America reflects a strong commitment to integrating cutting-edge technologies, promoting collaboration among academic institutions and biotech companies, ultimately fostering advancements in the South America Organ-On-Chip Market.As these applications evolve, they represent significant opportunities that align with global trends toward precision medicine and sustainable research practices. ### **Organ-On-Chip Market End-User Insights** The South America Organ-On-Chip Market has seen a notable focus on the End-User segment, which includes Pharmaceutical Companies, Research Organizations, and Others. Pharmaceutical Companies are pivotal in driving innovation, as they utilize organ-on-chip technology for drug testing, significantly reducing the time and cost associated with traditional methods. This technology allows for more biologically relevant models, enhancing the accuracy of drug efficacy and safety assessments, thereby reducing the failure rate in clinical trials.  Research Organizations also play an essential role, leveraging organ-on-chip systems for academic and governmental studies that advance understanding of human physiology and disease modeling, reflecting the growing trend toward more personalized medicine approaches in South America.The Others category encompasses various entities, including biotechnology firms and regulatory bodies, which contribute to market vitality through collaborations, fostering innovation and research initiatives.  The South America Organ-On-Chip Market shows promise for substantial growth, heavily influenced by these End-User segments, which address significant healthcare challenges and offer opportunities for improved regulatory compliance and faster product development. As the region continues to bolster its R&D capabilities, the demand for organ-on-chip solutions is expected to rise, benefiting the overall healthcare landscape. ### **Organ-On-Chip Market Regional Insights** The South America Organ-On-Chip Market is experiencing notable growth across its diverse regional landscape. Brazil leads the charge in market expansion, fueled by strong government investments in biotechnology and a robust Research and Development ecosystem. Meanwhile, Mexico is emerging as a key player, leveraging its geographical proximity to the United States and access to innovative technologies that bolster its market presence. Argentina, with its advancing biopharmaceutical sector, presents significant opportunities for the Organ-On-Chip Market, as local companies and universities increasingly focus on developing innovative solutions for medical research. The Rest of South America is starting to adopt these technologies, highlighting a trend of increasing collaboration among nations to enhance their respective healthcare systems. This regional segmentation showcases the varying growth drivers, with factors such as healthcare needs, regulatory frameworks, and technological advancements compelling each country to prioritize advancements in organ-on-chip solutions, thereby enhancing their market dynamics and fostering competitive advantages within the industry. Overall, the South America Organ-On-Chip Market illustrates a promising outlook, with each region contributing to its trajectory through unique strengths and collaborative opportunities. ## **South America Organ-On-Chip Market Key Players and Competitive Insights:** The South America Organ-On-Chip Market is rapidly evolving as a significant player in the biotechnological landscape, driven by increased investments in research and development, favorable regulations, and a rising demand for innovative drug testing methods. This market is characterized by a competitive environment where various companies are striving to enhance their technological capabilities, address specific regional healthcare challenges, and cater to a growing base of customers.  The integration of organ-on-chip technologies into research processes demonstrates vast potential for personalized medicine, toxicology testing, and disease modeling, significantly impacting the drug development pipeline. As a result, understanding the nuances of competition within this sector is crucial for stakeholders aiming to position themselves effectively in this burgeoning marketplace.Blacktrace has established a noteworthy presence in the South American Organ-On-Chip Market, leveraging its expertise in microfluidics and bioengineering to deliver state-of-the-art solutions. The company excels in developing innovative organ-on-chip platforms that replicate human organ functions accurately, facilitating advanced drug testing while reducing reliance on animal models. Blacktrace stands out for its commitment to pioneering technologies that enhance the reliability of preclinical testing, which is a vital aspect for researchers in the region focused on developing new therapeutics.  The firm has cultivated significant partnerships with local research institutions and biopharmaceutical companies, aiming to integrate its organ-on-chip technologies into various research initiatives across South America, thereby positioning itself as a trusted entity in this competitive landscape.Mimetas has carved out a recognizable niche in the South American Organ-On-Chip Market through its comprehensive suite of organ-on-chip products and services, which target various applications in drug discovery and development. The company’s flagship products are instrumental in providing highly predictive human tissue models, enabling researchers to obtain relevant data while minimizing experimental variability. Mimetas is well-regarded for its innovative designs and application versatility, allowing clients in academia and industry to tailor solutions to their unique research needs.  The company has been active in forging strategic alliances and partnerships to expand its market presence in South America, allowing it to access new clients and enhance its service offerings. Mimetas’ commitment to advancing organ-on-chip technology through continuous innovation and collaboration has further solidified its standing as a leader in the regional market, facilitating improvements in healthcare outcomes and fostering a more sustainable approach to drug discovery in the region. ### **Key Companies in the South America Organ-On-Chip Market Include:** ## **South America Organ-On-Chip Market Industry Developments** The South America Organ-On-Chip Market has seen significant developments recently, highlighting the continued growth and innovation in this sector. The demand for advanced drug testing systems and personalized medicine is increasing, with companies like Blacktrace, Mimetas, and TissUse focusing on developing sophisticated organ models to better mimic human physiology. In August 2023, Axiogenesis announced a partnership with a major Brazilian research institution, enhancing their research capabilities within South America. Additionally, Insphero launched a new line of organ-on-chip products tailored for local markets in September 2023, signaling a commitment to fulfilling regional needs.  Moreover, a notable acquisition occurred when Kereos acquired technology from a local startup in May 2023, aimed at improving their organ-on-chip platforms, strengthening their foothold in the region. The South American market has also experienced increased funding, with Biolamina and Aurelia Bioscience securing investments to expand their operations, thereby impacting the overall market valuation positively. In recent years, a growing interest in organ-on-chip technology, especially for its applications in toxicology and pharmaceuticals, has driven the market's valuation to exceed several million dollars, positioning it as a key area of investment and research. ## **South America Organ-On-Chip Market Segmentation Insights** ### **Organ-On-Chip Market Organ Type****Outlook** ### **Organ-On-Chip Market Application****Outlook** ### **Organ-On-Chip Market End-User****Outlook** ### **Organ-On-Chip Market Regional****Outlook** ## Market Drivers ### Support from Government Initiatives Government initiatives in South America are playing a crucial role in shaping the organ on-chip market. Various funding programs and grants aimed at promoting biotechnology research are being introduced, which directly benefit the development of organ-on-chip technologies. For instance, several South American countries have established biotechnology innovation funds that support research projects focused on organ-on-chip applications. This financial backing is likely to stimulate innovation and collaboration among academic institutions and private companies. As a result, the organ-on-chip market is expected to expand, with increased investment leading to advancements in technology and applications. The proactive stance of governments in fostering biotechnological advancements could significantly enhance the growth prospects of the organ-on-chip sector. ### Growing Demand for Personalized Medicine The organ on-chip market in South America is experiencing a surge in demand for personalized medicine. This trend is driven by the increasing recognition of the need for tailored therapeutic approaches that consider individual genetic and phenotypic variations. As healthcare providers and researchers seek to develop more effective treatments, organ-on-chip technologies offer a promising solution by enabling the simulation of human organ responses to various drugs. The market for personalized medicine is projected to reach approximately $2.5 billion by 2026 in South America, indicating a robust growth trajectory. This demand is likely to propel advancements in organ-on-chip technologies, as they provide critical insights into drug efficacy and safety, thereby enhancing the overall drug development process. ### Advancements in Microfabrication Techniques Recent advancements in microfabrication techniques are significantly influencing the organ on-chip market in South America. Innovations in materials science and engineering have led to the development of more sophisticated and reliable organ-on-chip models. These advancements allow for the creation of more complex tissue structures that closely mimic human physiology. As a result, researchers can conduct more accurate drug testing and disease modeling. The market for microfabrication technologies is expected to grow at a CAGR of around 15% over the next five years, which will likely benefit the organ-on-chip sector. Enhanced microfabrication capabilities not only improve the functionality of organ-on-chip devices but also reduce production costs, making them more accessible to research institutions and pharmaceutical companies. ### Rising Awareness of Ethical Research Practices The organ on-chip market in South America is witnessing a rise in awareness regarding ethical research practices. As researchers and institutions strive to minimize the use of animal testing, organ-on-chip technologies present an ethical alternative that aligns with the principles of the 3Rs: Replacement, Reduction, and Refinement. This shift towards more humane research methodologies is likely to encourage the adoption of organ-on-chip systems in academic and industrial settings. Furthermore, regulatory bodies are increasingly advocating for the use of alternative testing methods, which may further bolster the market. The ethical implications of organ-on-chip technologies could lead to a broader acceptance and integration into research protocols, thereby enhancing their market presence. ### Increasing Focus on Drug Development Efficiency The organ on-chip market in South America is being propelled by an increasing focus on drug development efficiency. Pharmaceutical companies are under pressure to reduce the time and costs associated with bringing new drugs to market. Organ-on-chip technologies provide a platform for high-throughput screening and predictive modeling, which can significantly streamline the drug discovery process. By utilizing these technologies, companies can potentially reduce the time to market by up to 30%, thereby enhancing their competitive edge. The growing need for efficient drug development processes is expected to drive investments in organ-on-chip technologies, as they offer a viable solution to the challenges faced in traditional drug testing methods. ## Future Outlook The [Organ on chip Market](https://www.marketresearchfuture.com/reports/organ-on-chip-market-8498) is projected to grow at 3.72% CAGR from 2025 to 2035, driven by advancements in biotechnology, regulatory support, and increasing demand for personalized medicine. **New opportunities:** - Development of customized organ-on-chip platforms for drug testing - Partnerships with pharmaceutical companies for integrated research solutions - Expansion into educational institutions for research and training programs By 2035, the organ on-chip market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Organ Type: Lung-on-Chip (Largest) vs. Kidney-on-Chip (Fastest-Growing) In the South America organ on-chip market, the distribution of market share is significantly tilted towards Lung-on-Chip technology, which has established itself as the largest segment due to its critical applications in respiratory research and drug testing. Following closely are Liver-on-Chip and Heart-on-Chip segments, which are gaining traction as they contribute valuable insights for related medical fields. Other segments, such as Kidney-on-Chip and Intestine-on-Chip, although smaller, are increasingly recognized for their innovative applications in nephrology and gastrointestinal studies. Growth trends in the South America organ on-chip market indicate a robust rise in research and development investments, particularly in the Kidney-on-Chip segment, which is currently marked as the fastest-growing. This growth is driven by the increasing need for personalized medicine and the demand for more reliable drug testing methods. Additionally, awareness of the benefits of organ-on-chip technology over traditional models encourages adoption across various sectors, further propelling the overall market forward. Lung-on-Chip (Dominant) vs. Kidney-on-Chip (Emerging) The Lung-on-Chip segment is characterized by its dominance in the South America organ on-chip market, primarily due to its advanced capabilities in simulating human lung responses under various physiological conditions. This technology plays a critical role in respiratory disease research and has become instrumental for pharmaceutical companies in drug development. Conversely, the Kidney-on-Chip segment is emerging rapidly as research intensifies in renal disease treatment and therapy responses. It offers an innovative approach to nephrology by mimicking kidney functions, showcasing an increasing demand for customized organ modeling. As research tools, both segment values offer unique advantages that contribute to improving the overall understanding of organ-specific diseases. ### By Application: Drug Discovery (Largest) vs. Toxicology Research (Fastest-Growing) In the Application segment, Drug Discovery commands a significant share of the market, underpinned by its critical role in developing new therapeutic treatments. This segment utilizes organ on-chip technologies to simulate human organs, facilitating a more efficient and cost-effective approach to drug testing. On the other hand, Toxicology Research is rapidly gaining traction, leveraging advancements in organ-on-chip platforms to offer innovative solutions for assessing drug safety and environmental impact, making it a key area of growth within the sector. The growth of both Drug Discovery and Toxicology Research is driven by the increasing demand for personalized medicine and the need for more accurate preclinical testing methods. Factors such as regulatory pressures for safer pharmaceuticals and the rise of Biotech firms venturing into organ-on-chip technologies are propelling the Toxicology Research segment. Furthermore, collaborations between research organizations and technology developers enhance the capacity for innovation, with Toxicology Research being positioned to become a fundamental aspect of pharmaceutical development processes. Drug Discovery (Dominant) vs. Toxicology Research (Emerging) Drug Discovery has emerged as the dominant force within the Application segment due to its extensive application in therapeutic advancements and clinical trials. It effectively streamlines the evaluation process by integrating human physiology into experimental designs, thereby reducing dependency on traditional animal testing. Conversely, Toxicology Research is classified as an emerging segment, rapidly evolving to address the critical need for efficient safety evaluations in drug development. It focuses on understanding the adverse effects of chemical compounds using organ-on-chip systems, which simulate real human biological responses. Both segments exhibit unique characteristics: while Drug Discovery is characterized by established methodologies and significant market investments, Toxicology Research is distinguished by its innovative approaches, appealing to an increasing number of stakeholders seeking cutting-edge solutions in drug safety assessments. ### By End-User: Pharmaceutical Companies (Largest) vs. Research Organizations (Fastest-Growing) In the South America organ on-chip market, pharmaceutical companies hold the largest share, dominating the landscape due to their significant investment in advanced drug development and testing methodologies. They utilize organ-on-chip technologies to enhance the efficiency of drug testing processes, reducing the time and cost associated with bringing new drugs to market. Meanwhile, research organizations are gaining traction, reflecting a growing demand for innovative research techniques that improve understanding of human biology and disease mechanisms. The growth of the end-user segment is driven by an increasing need for personalized medicine and the demand for more accurate preclinical testing models. Pharmaceutical companies benefit from the proven efficacy of organ-on-chip systems in drug discovery, while research organizations are rapidly adopting these technologies to enhance their experimental capabilities. This trend signifies a shift towards more efficient methodologies that are likely to sustain growth in both segments in the coming years. Pharmaceutical Companies (Dominant) vs. Research Organizations (Emerging) Pharmaceutical companies are characterized by their robust infrastructure and established pipelines for drug development, leveraging organ-on-chip solutions to streamline experiments and enhance predictive accuracy. These companies are deeply integrated into the healthcare landscape, benefiting from partnerships with regulatory bodies and academic institutions. In contrast, research organizations represent an emerging segment that is increasingly adopting organ-on-chip technologies to drive innovative studies in areas like toxicology and disease modeling. They focus on translational research, bridging the gap between basic science and clinical application, and their adaptive nature allows them to quickly implement new technologies and methodologies. Together, these segments reflect a dynamic interplay of established practices and innovative research in the South America organ on-chip market. ## Regional Market Share Analysis ### Brazil : Innovation and Investment Drive Growth Brazil holds a dominant 15.0% market share in the organ-on-chip sector, valued at approximately $150 million. Key growth drivers include increasing investment in biotechnology and a rising demand for personalized medicine. Regulatory support from the Brazilian Health Regulatory Agency (ANVISA) has fostered innovation, while infrastructure improvements in research facilities enhance production capabilities. The growing trend towards in vitro testing is reshaping consumption patterns, aligning with global shifts towards sustainable practices. ### Mexico : Regulatory Support Fuels Development Mexico captures a 7.5% share of the organ-on-chip market, valued at around $75 million. The growth is driven by government initiatives aimed at boosting the biotech sector, including funding for research and development. Demand for organ-on-chip technologies is rising, particularly in pharmaceutical testing and toxicology. The Mexican government is actively promoting partnerships between academia and industry, enhancing the local ecosystem for innovation and commercialization. ### Argentina : Research Institutions Lead Innovation Argentina holds a 5.0% market share in the organ-on-chip sector, valued at approximately $50 million. The market is driven by a strong emphasis on research and development, particularly in universities and research institutions. Demand for organ-on-chip technologies is growing in drug discovery and disease modeling. Government policies supporting scientific research and international collaborations are crucial for market expansion, alongside investments in infrastructure to support biotech startups. ### Rest of South America : Regional Collaboration Enhances Growth The Rest of South America accounts for a 5.35% share of the organ-on-chip market, valued at about $53.5 million. Growth is fueled by increasing collaboration among countries in the region, focusing on shared research initiatives and technology transfer. Demand is particularly strong in countries like Chile and Colombia, where regulatory frameworks are evolving to support biotech innovations. Local players are emerging, but competition remains limited compared to larger markets like Brazil and Mexico. ## Competitive Benchmarking The organ on-chip market in South America is characterized by a dynamic competitive landscape, driven by advancements in biotechnology and increasing demand for personalized medicine. Key players such as Emulate (US), TissUse (DE), and Mimetas (NL) are at the forefront, each adopting distinct strategies to enhance their market presence. Emulate (US) focuses on innovation through the development of advanced organ-on-chip platforms that mimic human physiology, thereby attracting partnerships with pharmaceutical companies for drug testing. TissUse (DE) emphasizes regional expansion, having recently established collaborations with local universities to foster research and development, which enhances its operational capabilities. Mimetas (NL) is leveraging digital transformation by integrating AI into its organ-on-chip systems, which allows for more precise modeling of human responses to drugs, thus shaping the competitive environment towards a more technology-driven approach.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. The market structure appears moderately fragmented, with several players vying for dominance. However, the collective influence of major companies is significant, as they drive innovation and set industry standards. This competitive structure fosters an environment where collaboration and strategic partnerships are essential for growth and sustainability. In October Emulate (US) announced a strategic partnership with a leading South American pharmaceutical firm to enhance drug development processes using its organ-on-chip technology. This collaboration is expected to streamline clinical trials and reduce time-to-market for new therapies, indicating a shift towards more localized solutions in drug testing. The strategic importance of this partnership lies in its potential to significantly impact the efficiency of drug development in the region, aligning with the growing trend of personalized medicine. In September TissUse (DE) launched a new organ-on-chip model specifically designed for metabolic studies, which has garnered attention from research institutions across South America. This innovation not only strengthens TissUse's product portfolio but also positions the company as a leader in metabolic research applications. The introduction of this model reflects the increasing demand for specialized organ-on-chip solutions that cater to specific research needs, thereby enhancing TissUse's competitive edge. In August Mimetas (NL) secured a funding round aimed at expanding its AI capabilities within its organ-on-chip platforms. This investment is likely to accelerate the development of more sophisticated models that can predict human responses with greater accuracy. The strategic importance of this funding lies in its potential to enhance Mimetas's market position by offering cutting-edge technology that meets the evolving demands of pharmaceutical research. As of November current competitive trends in the organ on-chip market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is expected to evolve, with a notable shift from price-based competition to a focus on technological advancements, innovation, and supply chain reliability. This transition underscores the importance of developing robust, reliable solutions that meet the complex needs of the market. ## Recent News & Developments The South America Organ-On-Chip Market has seen significant developments recently, highlighting the continued growth and innovation in this sector. The demand for advanced drug testing systems and personalized medicine is increasing, with companies like Blacktrace, Mimetas, and TissUse focusing on developing sophisticated organ models to better mimic human physiology. In August 2023, Axiogenesis announced a partnership with a major Brazilian research institution, enhancing their research capabilities within South America. Additionally, Insphero launched a new line of organ-on-chip products tailored for local markets in September 2023, signaling a commitment to fulfilling regional needs.  Moreover, a notable acquisition occurred when Kereos acquired technology from a local startup in May 2023, aimed at improving their organ-on-chip platforms, strengthening their foothold in the region. The South American market has also experienced increased funding, with Biolamina and Aurelia Bioscience securing investments to expand their operations, thereby impacting the overall market valuation positively. In recent years, a growing interest in organ-on-chip technology, especially for its applications in toxicology and pharmaceuticals, has driven the market's valuation to exceed several million dollars, positioning it as a key area of investment and research. ## Report Scope | MARKET SIZE 2024 | 32.85(USD Million) | | --- | --- | | MARKET SIZE 2025 | 34.08(USD Million) | | MARKET SIZE 2035 | 49.1(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.72% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Emulate (US), TissUse (DE), Mimetas (NL), Organovo (US), Synlogic (US), Hesperos (US), InSphero (CH), Reinnervate (GB), Tissot (FR) | | Segments Covered | Organ Type, Application, End-User | | Key Market Opportunities | Growing demand for personalized medicine drives innovation in the organ on-chip market. | | Key Market Dynamics | Rising investment in Research and Development drives innovation in organ on-chip technologies across South America. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What is the projected market valuation for the organ on-chip market in South America by 2035?** A: The projected market valuation for the organ on-chip market in South America is $49.1 Million by 2035. **Q: What was the overall market valuation for the organ on-chip market in South America in 2024?** A: The overall market valuation for the organ on-chip market in South America was $32.85 Million in 2024. **Q: What is the expected CAGR for the organ on-chip market in South America during the forecast period 2025 - 2035?** A: The expected CAGR for the organ on-chip market in South America during the forecast period 2025 - 2035 is 3.72%. **Q: Which organ-on-chip types are projected to have the highest valuations in South America?** A: The organ-on-chip types projected to have the highest valuations include Liver-on-Chip at $8.0 Million and Lung-on-Chip at $7.0 Million. **Q: What applications are driving growth in the organ on-chip market in South America?** A: The applications driving growth include Drug Discovery, projected to reach $18.5 Million, and Toxicology Research, expected to reach $22.0 Million. **Q: Who are the key players in the South America organ on-chip market?** A: Key players in the South America organ on-chip market include Emulate, TissUse, Mimetas, Organovo, and Synlogic. **Q: What is the valuation range for the Kidney-on-Chip segment in South America?** A: The valuation range for the Kidney-on-Chip segment in South America is between $4.0 Million and $5.5 Million. **Q: Which end-users are contributing to the organ on-chip market in South America?** A: End-users contributing to the organ on-chip market include Pharmaceutical Companies, with a valuation range of $12.85 Million to $18.5 Million. **Q: What is the valuation range for the Skin-on-Chip segment in South America?** A: The valuation range for the Skin-on-Chip segment in South America is between $3.0 Million and $4.0 Million. **Q: How does the organ on-chip market in South America compare to other regions?** A: While specific comparisons to other regions are not provided, the growth trajectory in South America appears promising with a projected valuation increase to $49.1 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-organ-on-chip-market-51313*